Invictus's Acreage
Pharms Launches Innovative, Ambitious Extraction Program for
Cannabis Oils
Vancouver, BC -- January
31, 2018 -- InvestorsHub NewsWire
-- INVICTUS MD STRATEGIES CORP.'s
("Invictus" or the
"Company") (TSXV: IMH; OTC: IVITF; FRA: 8IS1) Acreage Pharms
Ltd.
("Acreage
Pharms") is pleased to announce
the acquisition of cannabis oil extraction
equipment and the hiring of key
professionals to launch an extraction program to serve Canada's
expanding need for high-quality cannabis oils.
The C02
extraction technology, on track for production, will use
Acreage Pharm's cannabis to
extract
and manufacture
cannabis
oils. Acreage Pharms will
apply for an oil license from Health Canada as soon as it receives
sales licenses expected.
The
acquisition of a closed-loop C02 extraction system is essential for
Acreage Pharms market strategy. The system performs Subcritical and
Supercritical Fluid Extraction utilizing high-pressure carbon
dioxide to extract essential oils from botanicals, using specific
temperatures and pressures to withdraw different components from
plants. The innovative process produces the highest-quality
cannabis oils in the world.
Compared
to solvent extractions, Acreage Pharms Supercritical C02
extraction will be:
Non-Toxic/Non-Carcinogenic. Oils extracted using
this technology do not contain
petroleum
particles.
Safe. The system does not
use potentially flammable or explosive petroleum-based
solvents.
Carbon-Neutral/Environmentally
Friendly. The system does not
emit carbon into the atmosphere.
Customizable. With a wide range of
temperatures, pressures and flow rates to leverage, the system is
capable of fully withdrawing from botanicals like cannabis full
profiles of natural compounds.
Premium quality. The advanced system is
used by the best companies to extract coffee, vanilla, tea, fruit
and nut extracts and aromas, omega-3 oils, fragrances, perfumes,
tobacco extractions for e-cigarettes, hop-oil extraction for beer,
oil extractions for alternative energies from algae and high-grade
cannabis oil.
Supercritical C02
extraction offers the blossoming cannabis industry the promise of
understanding the myriad medical benefits of cannabis. By giving
concentrate makers so much control over the process, it gains them
access to cannabinoids within the plant beside THC and CBD, which
some researchers believe will be vital components of ongoing
cannabis research and development.
Both the
Phase 1 and Phase 2 facilities at Acreage
Pharms have a total of
approximately 40,000 square feet with expected 5,000 kg of capacity
beginning in February 2018 along with a further planned 80,000
square foot Phase 3 expansion for
total combined
production
capacity at
Acreage Pharms of 19,000 kg
in
2018.
This will be ample supply to conduct oil extraction,
processing and development to supply the expanding medical market
and to prepare for the recreational market later this
year.
The
ambitious new technology program requires the guidance, oversight
and scientific savvy of seasoned professionals, and Acreage Pharms
is thrilled to add Chris
Kooner,
RPh
and
Dr.
Dejun
Cui to the
team. Both of these pharmacy
and agriculture veterans have been with Acreage for six months, but
now are pivoting their responsibilities towards the new oils
extraction program.
Chris
will take over as Responsible Person in Charge (RPIC) for Acreage
Pharms. Chris, a registered pharmacist with years of executive
experience in pharmacy production labs, has dedicated much of his
career to building safe, efficient production protocols at large
pharmacies and then managing all aspects of production within
pharmacies. This work is extremely detailed and grounded in
science, and parallels
cannabis
oils production. With such broad experience in both the
pharmaceutical and now cannabis industries, Chris has the full
scope of knowledge.
Dr. Cui
will oversee Quality Assurance at Acreage Pharms. His long list of
key responsibilities and duties includes:
* Developing a protocol
for sampling and testing dried cannabis to ensure representative
results for the batch and the microbial and chemical contaminants
meet the specifications.
* Ensuring all
products
prior to
release for sale is analyzed for pesticide
residues to
verify their absence.
* Ensuring that cannabis
oil must not contain residues of prohibited solvents.
With more
than 30 years of high-level experience in horticulture
and
agriculture Dr. Cui is ideal for this mission-critical position.
Among other things, Dr. Cui has more than 25 years experience in
Integrated Pest Management, with specialties in biological control
agents, physical control, botanical/bio-pesticides, entomology,
plant pathology, agronomy and greenhouse and growth chamber
management. He also has extensive experience working with
the Cannabis sativa plant in professional
settings.
"Building
a scientifically rigorous, safe and productive extraction program
has long been an Invictus
goal," said
Dan Kriznic,
Chairman and CEO of Invictus.
"With our cannabis production ramping-up on schedule, we now are
prepared to begin crafting the high-quality oils for Canada's
growing medical market, as well as the anticipated recreational
market set to launch in July 2018. Our acquisition of the latest
extraction technology, along with the addition to our team of
agricultural and pharmacy professionals with advanced degree and
decades of combined experience, sets our extraction program on
strong footing immediately."
About Invictus MD
Strategies Corp.
Invictus
MD
Strategies Corp. is focused on two main verticals within the
Canadian cannabis sector, namely
the Licensed Producers under the ACMPR, being its 100% investment
in Acreage Pharms Ltd., located in West-Central Alberta, and
50% investment
in
AB
Laboratories Inc., located near Hamilton, Ontario
which has
both its cultivation and sales license under
ACMPR. Combined the two
licenses and an expected
third
license
under AB
Ventures Inc. are expected to
have
an
approximate
annual
run-rate
production capacity of
76,000 kg by
2019.
In addition to ACMPR licenses the Company has an 82.5% investment
in Future Harvest Development Ltd. a Fertilizer and
Nutrients manufacturer
based in Kelowna, British Columbia.
For more information,
please visit www.invictus-md.com.
On Behalf of the
Board,
Dan Kriznic
Chairman
&
CEO
Larry
Heinzlmeir
Vice
President, Marketing & Communications
604-537-8676
Although
management of the Company has attempted to identify important
factors that could cause actual results to differ materially from
those contained in forward-looking statements or forward-looking
information, there may be other factors that cause results not to
be as anticipated, estimated or intended. There can be no assurance
that such statements will prove to be accurate, as actual results
and future events could differ materially from those anticipated in
such statements. Accordingly, readers should not place undue
reliance on forward-looking statements and forward-looking
information. Readers are cautioned that reliance on such
information may not be appropriate for other purposes. The Company
does not undertake to update any forward-looking statement,
forward-looking information or financial out-look that are
incorporated by reference herein, except in accordance with
applicable securities laws. We seek safe harbor.recreational use of
cannabis in Canada will not occur at all or as expected.
, that the
anticipated sales of inventory will not occur on the terms and
timing expected by management or at all, that the Transaction will
not complete on the expected terms or at all and that the
legalization of successfully complete
its expansion plansobtain the anticipated
sales license when expected by management or at all or is not able
to Acreage Pharms is not
able to that ,AB Ventures is not able
to successfully build a production facilitythat , or will not receive a
development permit on the expected terms or at
allAB
Ventures will not be granted a license under the
ACMPRthat reach full production
capacity, will not
Acreage
Pharms orAB Labs, AB
Ventures that their full production
capacity or at all, for . These forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, level of
activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Important factors that may cause actual results to vary, include,
without limitation, the risk that AB Labs, AB Ventures and Acreage
Pharms will not receive regulatory approval to sell medical
cannabis at their production facilitiesrecreational use of
cannabis in Canada will occur as expected, the anticipated sales
of inventory will take place on the terms and timing expected by
management, all conditions to the closing of the Transaction will
be satisfied and the Transaction will complete on the terms set out
in the definitive agreement and that the legalization of
complete its
expansion plansobtain the anticipated
sales license and will successfully successfully
and
satisfy all
conditions for Acreage Pharms
will,, AB Ventures is able to
successfully build a production facility and will receive a
development permit on the expected termsbe granted a license
under the ACMPRand satisfy all conditions
for regulatory approval to
sell medical cannabis at their production facilities' full
capacity, AB Ventures will , receive
satisfy all
conditions for, andAB Labs, AB Ventures and
Acreage Pharms willthat are forward-looking
statements and contain forward-looking information. Generally,
forward-looking statements and information can be identified by the
use of forward-looking terminology such as "intends" or
"anticipates", or variations of such words and phrases or
statements that certain actions, events or results "may", "could",
"should", "would" or "occur". Forward-looking statements are based
on certain material assumptions and analysis made by the Company
and the opinions and estimates of management as of the date of this
press release, including the assumptions pursuant to the
definitive agreement (the "Transaction") AB
Labsin the Company's
ownership ofincrease
expansion
plans, expected sales of inventory and the completion of the
and the
success and timing of Acreage Pharms'sales license
areceipt of
Acreage
Pharms',assumptions or
expectations of future performance, including the potential
production capacity of AB Labs, AB Ventures and Acreage Pharms'
production facilities, the granting of regulatory approval and
anticipated timing of AB Labs reaching full production capacity,
the granting of a sales license under the ACMPR to AB Ventures and
Acreage Pharmstiming,
Cautionary
Note Regarding Forward-Looking Statements: This release includes
certain statements and information that may constitute
forward-looking information within the meaning of applicable
Canadian securities laws or forward-looking statements within the
meaning of the United States Private Securities Litigation Reform
Act of 1995. All statements in this news release, other than
statements of historical facts, including statements regarding
future estimates, plans, objectives,
Neither
the TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
Invictus MD Strategies (CE) (USOTC:IVITF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Invictus MD Strategies (CE) (USOTC:IVITF)
Historical Stock Chart
From Sep 2023 to Sep 2024